It is estimated that over 1.5 million children are infected with the human immunodeficiency virus (HIV) worldwide. 1 From the beginning of the HIV pandemic through mid-1996, there were approximately 3 million cases of paediatric AIDS, 90% coming from sub-Saharan Africa. 2 The pathophysiology of HIV infection in children is poorly known. The relationship between infection with the virus and growth of children is not well described in sub-Saharan Africa or other lesser developed country settings where antiretroviral therapy has not been available and children are often at risk of undernutrition. Several studies have found both HIV-infected and uninfected children of HIV-infected mothers to be smaller and to weigh less than uninfected children of uninfected mothers from birth [3] [4] [5] [6] [7] up to 70 months of age. [8] [9] [10] [11] [12] [13] It is unclear whether, and to what degree, growth failure is a direct consequence of vertically acquired HIV infection, is secondary to HIV-related clinical illness in the child, or is a function of the child's adverse environment. Many infected children are born into families at risk for undernutrition, infectious diseases, and sources of morbidity that could lead to child growth retardation. Maternal HIV disease progression is associated with increased risk of perinatal transmission, 14, 15 and in Europe, the health of the newborn infant varies directly with the severity of HIV-related disease in the mother at birth, 16 but no studies have shown whether immunosuppresion, illness, or socioeconomic conditions of the HIV-infected mother are related to growth stunting or wasting in infected infants in a lesser developed country setting. Data on infant growth according to maternal immunological and sociodemographic factors are needed from lesser developed countries to devise strategies for preventive, clinical, and social services for HIV-infected mothers and their infants and to make accurate projections concerning the global impact of HIV on child morbidity and mortality.
We report the results of a prospective cohort study of HIVinfected and uninfected mothers and their infants in Kinshasa, Democratic Republic of Congo (formerly Zaire) from 1989 to 1992. Anthropometric measurements of infants from birth to age 20 months and immunological and sociodemographic data on mothers are presented to determine growth progression in HIV-infected children in a setting where antiretroviral therapy and food supplementation are unavailable. We estimate the risk for child growth retardation according to child and maternal immunological factors, severity of maternal and child illness, and maternal socioeconomic status.
Methods
Details about enrolment and follow-up procedures have been described elsewhere. 15 Briefly, between October 1989 and April 1990, pregnant women at two large hospitals in Kinshasa, Congo, were offered HIV-1 testing and counselling, according to a protocol approved by the Ethical Committee of the Ministry of Health of Zaire. Consenting women who tested positive for HIV-1 antibody by rapid test and enzyme immunoassay and who were confirmed as infected by Western blot were considered HIV-infected. All HIV-infected women and their children were recruited for follow-up. For 4 months, consenting HIV seronegative women matched by age (within 2 years) and parity were also enrolled at the same two hospitals; these women were retested for HIV seroconversion 12 months post partum. Children were monitored until September, 1992 (mean age 18 months; range, 13-24 months). At enrolment, mother's age, place and type of residence, and other demographic variables were recorded. Her standing height was measured and other clinical evaluation was performed two or three days post partum.
At delivery all enrolled mothers underwent a number of tests including: a physical exam with scoring according to a modified World Health Organization clinical case definition for AIDS; automated complete blood cell count; manual white blood cell differential; determination on site of CD3/CD4 and CD3/CD8 lymphocyte counts; determination of HIV-1 p24 antigen; and thick smear for malaria. Blood for lymphocyte and antigen studies was collected 24-72 h after delivery. History of the pregnancy, labour, delivery and neonatal course were recorded, as was age, and whether the mother was married or living with a male partner. For purposes of estimating socioeconomic status, self-reports on type of housing and a list of material possessions were recorded.
Children were seen monthly from 3-12 months and bimonthly thereafter. Polymerase chain reaction (PCR) for HIV was performed on bloods drawn at the 2-day and 3-month visits. An HIV infection in children was defined as a positive virological assay (PCR or viral culture) on two or more specimens drawn on different days or a persistently positive HIV antibody assay at 15 months or later. Uninfected children were defined as those who were HIV antibody-negative and whose virological assays were all negative. Other children were classified as HIV-indeterminate. Other serological and clinical exams included recumbent length, weight, CD3, CD4 and CD8 counts, and WHO stage of illness.
Standard normal deviates (z-scores) for length for age, weightfor-age, and weight-for-length were calculated for each child using the program EPINUT, 17 which uses the growth reference curves developed by the National Center for Health Statistics (NCHS) and Centers for Disease Control and Prevention (CDC) generated from data from the Fels Research Institute and US Health Examination Surveys. 18 For multivariate analyses, -2.00 z-scores was used as the cutoff for low anthropometric values. The log-rank statistic was used to compare the Kaplan-Meier curves for each of three groups surviving to -2.00 z-scores for length-for age, weight-for-age, and weight-for-height. Extended Cox proportional hazard models with time dependent variables were run to estimate the risk of reaching Ͻ-2.00 z-scores during 18 months of follow-up. 19 In order to assess the effects of childspecific independent variables independently of mother-specific variables on growth retardation, models containing child variables were run separately from those containing mother variables and from those containing both child and mother variables. The child-specific variables included in the models were: Group (infected, uninfected, control), gender, adenopathy (present, absent), immune status (normal, moderate, severe; based on CD4+ count as per cent of total lymphocytes, normal Ͼ25, moderate 15-24, severe Ͻ15), low CD4/CD8 ratio at 3 months (Ͻ0.75), diarrhoea (presence of у3 stools per day for у4 days since last visit), persistent diarrhoea (presence of у3 stools per day for Ͼ14 days since last visit), persistent fever (presence of fever for Ͼ14 days since last visit). The mother-specific variables included in the models were: HIV serostatus, WHO clinical stage of illness (Stage 1, 2, 3), 20 CD4 count at delivery and at 12 months (low Ͻ200, moderate 200-499, normal Ͼ499), low haemoglobin count (Ͻ0.85 g/l), socioeconomic status (low, middle, high; based on classification of a self-reported inventory of possessions), partner (present or absent), age (Ͻ20, у20), and stature (short, medium, tall). No multicollinearity among variables was detected by inspection of condition indices. Interaction terms between HIV serostatus and all covariates were assessed and interaction terms were retained if found to be significant at the P Ͻ 0.05 level. Backward elimination procedures were used to estimate the hazard of falling below the -2.00 z-score cutoffs for length-for-age, weight-for-age, and weight-for-length.
Results
The 324 HIV-infected women who gave birth at the two study hospitals had 323 live-born infants. A laboratory diagnosis of perinatal HIV-1 infection was established in 261 children of seropositive women; of these 69 (26%) were classified as HIVinfected (Group 1); 191 as seronegative (Group 2); and 63 as indeterminant for HIV infection. There were 258 children born to 254 seronegative mothers (Group 3, Controls).
Differences between seropositive and seronegative women at delivery were summarized previously. 15 Table 1 summarizes the number of children in Group 1, Group 2 and Group 3 by gender and maternal characteristics. There were no differences between mothers of HIV-infected, HIV seronegative and control children in mean age, proportion Ͻ20 years, partner status (partner present or absent), socioeconomic status (three categories), or Tables 2, 3 and 4 compare the mean lengths, weights, weights-for-height and z-scores for children in Groups 1, 2 and 3. Mean z-scores for length, weight, and weight-for-length are graphically presented in Figures 1, 2 and 3. All children, regardless of HIV serostatus, were below the US reference population in length and weight. Controls started below the reference population in length at birth and became progressively stunted through age 20 months. In weight, Controls did not fall below the reference population until age 6 months and were at approximately -1.25 z-scores by age 16 months. In weight-forlength, Controls were similar to US children. These results suggest that, compared to the US reference population, Kinshasa children experienced moderate undernutrition and stunting, but that loss of length and weight was proportional, indicating that these children were not experiencing wasting.
There was no significant difference in mean length at birth between the three Groups of children. By 3 months of age, HIV-infected (Group 1) children were significantly shorter (P Ͻ 0.0001) than both uninfected (Group 2) and Control children, and Group 1 children remained significantly shorter compared to the other two groups through age 18 months. At 20 months, the sample size of Group 1 children was reduced to 14, and the power to detect a statistical difference between infected and uninfected children was limited (P = 0.081). The mean weights at birth of infected and uninfected children were similar to each other, but significantly less than that of Controls. By 3 months GROWTH OF HIV-INFECTED CHILDREN 535 Table 2 Lengths (mean cm ± SE) and z-scores (mean ± SE) by age in months of HIV-infected infants (Group 1), HIV-negative infants of HIV-infected mothers (Group 2), and HIV-negative infants of HIV-negative mothers (Group 3) of age, the mean weight of Group 2 children had caught up to Controls, while Group 1 children fell significantly below that of the other two groups and remained that way through age 20 months. The mean weights-for-length of Group 2 and Control children were the same from birth onwards. At 10 months of age these uninfected children became just slightly wasted compared to the US reference sample and remained that way until the end of the study. Group 1 children, although below the other two groups in mean weight-for-length at birth, were essentially the same as the other two Groups until 12 months. From then onwards, the infected children remained significantly wasted compared to uninfected and Control children throughout the 20-month follow-up period. A common cutoff for low anthropometric values is Ͻ-2.00 z-scores below the NCHS reference population. 17 Figure 4 shows the Kaplan-Meier survival plots for infected, uninfected and Control children surviving у-2.00 z-scores for length at Multivariate analyses were performed using extended Cox proportional hazards regression models for time dependent variables to estimate factors contributing to reaching Ͻ-2.00 z-scores during 18 months of follow-up. When only the childspecific independent variables were included in the multivariate analyses, being HIV-infected (Group 1) (relative risk [RR] = 2.38; CI = 1.58-3.57; P = 0.0001) and having prolonged diarrhoea (RR = 1.60; CI = 1.08-2.38; P = 0.020) were significant risk factors for falling below -2 z-scores in length-for-age. The risk factors for reaching low weight-for-age were HIV-infection (RR = 2.54; CI = 1.66-3.89; P = 0.0001), adenopathy (RR = 1.68; CI = 1.15-2.47; P = 0.008), severe immune suppression (RR = 2.75; CI = 1.36-5.58; P = 0.005), prolonged fever (RR = 2.11; CI = 1.12-3.98; P = 0.022), and male gender (RR = 1.40; CI = 1.05-1.87; P = 0.022). Being HIV-infected (RR = 3.32; CI = 1.96-5.61, P = 0.0001) and presence of adenopathy (RR = 2.26; CI = 1.34-3.83, P = 0.002) were significant risk factors for low weight-for-length. Thus HIV infection and associated illnesses were consistently and independently associated with growth retardation in length-for-age, weight-for-age, and weight-forlength by 18 months.
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No maternal variables emerged as significant factors associated with infant growth retardation except mother's stature. As could be expected, having a taller mother was protective against low length-for-age (RR = 0.43; CI = 0.20-0.95; P = 0.037) and low weight-for-age (RR = 0.41; CI = 0.17-0.95; P = 0.037), but mother's stature had no effect on weight-forlength.
When both child and maternal factors were included as independent variables in the Cox proportional hazards models, the results were unchanged from the results obtained by including only the child variables, except mother's stature emerged again as a significant factor. Having a taller mother was protective against low length-for-age (RR = 0.41; CI = 0.22-0.78; P = 0.006) and low weight-for-age (RR = 0.37; CI = 0.19-0.74; P = 0.002), but not for low weight-for-length (RR = 0.30; CI = 0.073-1.26; P = 0.10). When mother's stature was controlled for, the HIV-infected infant was 2.10 (CI = 1.30-3.39; P = 0.003) times more likely to be stunted, 2.84 (CI = 1.58-5.11; P = 0.001) times more likely to be underweight, and 2.56 (CI = 1.63-4.03; P = 0.001) times more likely to be wasted than the uninfected infant. Similarly, when the models with maternal variables were stratified by infant's HIV status, only mother being tall made a significant difference in time to retarded growth status. These results taken together indicate that the mother's age, socioeconomic status, spousal situation, HIV status, stage of illness, and immune status had no effect on the infant's risk of stunting, undernutrition, or wasting. It was the HIV infection and associated signs and symptoms in the infant, not the mother's immunological or socioeconomic circumstances, that placed children at risk for growth retardation.
Discussion
As with previous studies in sub-Saharan Africa, 6, 7, 13, 21, 22 we find that mean weights of newborns of HIV-infected mothers are lower than those of newborns of uninfected mothers. However, we do not detect differences in mean length at birth. Lower birthweights of infants born to seropositive women may be due to higher rates of preterm labour as found in several studies, 7, 21, 23, 24 but not in others. [25] [26] [27] Intrauterine growth retardation (IUGR) also occurs among infants of HIV-infected mothers, 21 most likely late in pregnancy. 6 Intrauterine growth retardation may depend on how advanced the HIV infection is in the mother, 7,22 but socioeconomic and psychocultural factors associated with maternal HIV infection cannot be ruled out.
The HIV-infected newborns in our study were not significantly smaller than uninfected newborns of infected mothers suggesting that HIV does not have direct effects on fetal growth. Reports from Haiti, 23 Europe, 10, 16, 28 and the US 8,9,11 have shown no significant differences in birthweight and gestational age between infected and uninfected infants of HIV positive mothers. When preterm delivery and low birthweight occur, they are thought to be related to drug abuse during pregnancy or a direct effect of the virus on the mother, 23 not to fetal HIV infection. Since most vertical HIV transmission is thought to occur late in pregnancy, any differences in size between HIVinfected and HIV-uninfected newborns is likely less the direct impact of viral infection of the fetus itself, and more the result of maternal coinfections, substance abuse, undernutrition, inadequate prenatal care, or other exposures associated with female HIV infection. This is consistent with results from studies of transgenic mice which have shown no stunting of embryos or neonates, but severe stunting and wasting beginning post partum. 29, 30 The one other published cohort study comparing growth in HIV-infected versus uninfected children in Africa is by LePage et al. from Rwanda. 13 Uninfected Rwandan infants and the Congolese infants in this study (Controls) have similar levels of undernutrition and stunting, both falling by age 18 months GROWTH OF HIV-INFECTED CHILDREN 537 Figure 4 Kaplan-Meier estimates of the proportion of infants remaining above -2.00 z-scores for length-for-age according to whether the infants are HIV positive, HIV negative, or Control to approximately -1.50SD to -2.00SD below the sex and agespecific NCHS reference values for weight and length. Such levels of undernutrition and stunting are similar to other African urban and rural poor. 31 Uninfected children of infected mothers (Group 2 infants) in both Rwanda and Congo weigh less at birth than Control newborns, but by age 3 months they exhibit 'catch up growth' 32 and these uninfected children remain the same weight as Control children over the period of follow-up. Infected (Group 1) children, on the other hand, start out significantly lighter than Control children and remain that way through the end of the study at age 20 months. Similarly for length, both Rwandan and Congolese infected children grow slower than uninfected children, while Group 2 children have the same mean length-for-age as Control children from age 3 months on.
While malnutrition and wasting are characteristic of adults infected with HIV regardless of the patient's location, 33 it has not been clear whether infected children suffer wasting (low weight-for-height) in the absence of food supplementation and antiretroviral therapy. 12 In the US, McKinney et al. 11 found that by 24 months, HIV-infected children were not abnormally lean or wasted. They were smaller in both length and weight than uninfected children, but they were proportionately smaller and lighter, making them normal for weight-for-length. A study by Saavedra et al., 9 following 59 HIV-infected and 50 uninfected children from birth to 70 months in Baltimore, Maryland, had similar results. In a longitudinal study over the first four years of life, the European Collaborative Study Group 16 found that infected children were on average 6% lighter and 2% shorter than uninfected children. Most of the weight difference was explained by differences in height, particularly after age one.
Since treatment with zidovudine has a positive effect on weight growth rates, 12 the studies from the US and Europe have questionable validity for understanding patterns of growth in children of lesser developed countries where such treatments are rarely, if ever, available, or when available, they are affordable to only an elite few. In the one US study in which children receiving antiretroviral therapy or supplemental feedings were excluded from analyses, 8 by the time of first follow-up at a mean of 19 months, infected children were significantly lighter, had significantly lower weight-for-length, and significantly less arm-muscle circumference (AMC) than uninfected children. This suggests that, in the absence of antiretroviral therapy, wasting and cachexia are the more typical pattern of disease progression in the HIV-infected children.
Our results indicate that HIV-infected Congolese infants do experience wasting after approximately the first year of life. In Rwanda, HIV-infected children were significantly wasted compared to uninfected children only periodically-at ages 3, 6, 24 and 36 months. The level of wasting at approximately -1.00SD was similar to our Congolese sample. 13 Cross-sectional and longitudinal studies have shown that persistent diarrhoea is strongly associated with malnutrition and HIV infection in this Congolese child population. Those children who were more severely wasted were more likely to experience a subsequent persistent episode of diarrhoea than those less wasted. 34 Wasting is both a result of and a precursor to the cyclic effects of episodic acute diarrhoea, malnutrition, and immune dysfunction. It is known that, independently of HIV infection, malnutrition reduces immunological function, impairs tissue repair, and compromises the child's ability to resolve acute diarrhoea. 35 Since the HIV-infected children in this study experienced wasting significantly more severe than the seronegative children of HIV-positive mothers, HIV infection is likely a causative factor initiating and maintaining the downward spiral of wasting. In any event, the results of this study support the conclusion that wasting is characteristic of HIV-infected children who do not have access to zidovudine or other immunosuppressing drugs.
The differences between seropositive and seronegative children in mean length-for-age, mean weight-for-age, and mean weight-for-length were statistically significant at most ages starting at 3 months, but in view of the considerable variation between individual children, these anthropometric measures cannot be used as indicators of infection. Since both the seropositive and seronegative children were undernourished compared to reference standards, nutritional interventions would be appropriate for many children in the African urban setting regardless of HIV serostatus.
It has been unclear whether, and to what degree the circumstances of the HIV-infected mother place the infected infant at risk for morbidity and growth retardation. Many studies suggest that the disease status of the HIV-infected mother compromises her ability to care for her infant. Advanced maternal disease is associated with low birthweight, low gestational age at delivery, and increased risk of infant mortality. 7 Maternal morbidity influences chronic stress and child survival in African children, 36 and the presence of a healthy mother is important to survival of children. 37 In Congo, uninfected children of seropositive mothers suffer nearly twice the incidence of persistent diarrhoea as uninfected children of seronegative mothers, and the incidence of infant diarrhoea increases with severity of maternal disease. 34 This suggests that mothers' caretaking abilities are impaired by their HIV-related disease leading to increased risk in their children for undernutrition, diarrhoea, and respiratory infections that would likely retard growth progression.
The results of our study, however, indicate that maternal immunological, clinical, and sociodemographic factors do not place children in Kinshasa at increased risk for growth retardation. The only significant maternal factor related to severe stunting or undernutrition in these Congolese children is mother's stature, a factor unrelated to her HIV status. Neither serostatus nor the level of immune suppression, nor any signs or symptoms of HIV-related illness in the mother are significantly related to growth retardation in the infant in this study. Presence or absence of a male partner, age, and socioeconomic status of the mother also have no effect. That tall stature in the mother has a protective effect against stunting in her child is not surprising in view of an heritable component to stature, 38 and in light of numerous studies from lesser developed countries showing that socioeconomic conditions leading to stunting in one generation are often passed to children in the next generation, 39 leading to the consensus that stature is a sensitive indicator of the socioeconomic environment. 40, 41 Remarkably, the women in this study classified as better off were not significantly taller than those classified as poor. This could be due to the relative homogeneity in socioeconomic status of women who report to the two hospitals from which study participants were recruited. The more affluent, 'elite' Congolese tended to seek treatment at private clinics or abroad.
The finding in this study that the mother's HIV-related symptoms had no apparent effect on the risk of her child experiencing slow growth may well be related to the lack of women in the study in the advanced stages of HIV-related illness. Only three women in the study were classified as WHO Clinical Stage 3 and only 20 women were WHO Clinical Stage 2. Thus very few had progressed in their illness to the point of having their child caretaking abilities impaired. It would be premature, based on the results of this study, to conclude that HIV-associated morbidity in the mother does not affect proper growth and development of her infant. Interventions targeted against the principal causes of maternal morbidity and toward household and community health 42, 43 are still likely to benefit children of HIV-infected mothers.
In conclusion, this study shows that in Congo where antiretroviral therapy is unavailable HIV-infected children aged 0-18 months suffer significant stunting, undernutrition, and wasting compared to uninfected children. Uninfected children of HIV seropositive mothers are similar at birth to infected infants, but by 3 months of age, they have the same anthropometric characteristics as children of seronegative mothers. We found no evidence that immunosuppression, illness, or socioeconomic conditions of the HIV-infected Congolese mother affect the growth of her child. Since, however, few of the women in our study were far progressed in their HIV illness, additional studies of child growth progression and characteristics of the HIV-infected mother are needed from lesser developed countries where 90% of the world's infected infants are born. Such studies will inform strategies for preventive, clinical, and social services for HIV-infected mothers and their infants and will allow accurate projections concerning the global impact of HIV on child morbidity and mortality. Most urgently needed are studies of different means of reducing perinatal HIV transmission in ways that, to be effective in lesser developed countries, are technologically simple, affordable, and adaptable to a wide variety of settings.
